At the time Sangamo said it would focus a Fabry treatment nearing Phase 3 testing its regulatory T cell therapy research and a neurology drug pipeline centered on epigenetic regulation. Now the company is deferring any further investment into its Fabry or Treg programs until it finds a partner or other outside funding